Download molecular diagnosis in lgmd2a: mutation analysis or

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

Genomics wikipedia , lookup

RNA-Seq wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

Microevolution wikipedia , lookup

Therapeutic gene modulation wikipedia , lookup

Mutation wikipedia , lookup

Neuronal ceroid lipofuscinosis wikipedia , lookup

Gene nomenclature wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

Epistasis wikipedia , lookup

Frameshift mutation wikipedia , lookup

Protein moonlighting wikipedia , lookup

Epigenetics of neurodegenerative diseases wikipedia , lookup

NEDD9 wikipedia , lookup

Point mutation wikipedia , lookup

Transcript
PROTEIN AND MOLECULAR DIAGNOSIS IN LGMD2A
A.C. Nascimbeni 1,2, L. Fulizio 1,2, M. Spinazzi 1,2, M. Fanin 1,2, C. Angelini 1,2
1
Department of Neurosciences, University of Padova; 2 Venetian Institute of Molecular Medicine,
Padova. Tel. 049.7923202. Fax: 049.7923250. E-mail: [email protected]
Limb girdle muscular dystrophy type 2A (LGMD2A) is caused by mutations in the CAPN3 gene
encoding for calpain-3, a muscle specific protease. The diagnosis of LGMD2A has recently shifted
from molecular genetics towards biochemical assay of defective protein. However, an estimate of
sensitivity and specificity of protein analysis remains to be established. Thus, we first correlated
protein and molecular data in our large LGMD2A patient population. By a preliminary immunoblot
screening of calpain-3 protein of 548 unclassified patients with various phenotypes (LGMD,
myopathy, hyperCKemia), we selected 270 cases for CAPN3 gene mutation analysis: 83 had
protein deficiency and 187 had normal expression. Mutation search was conducted using SSCP,
DHPLC, ARMS-PCR and direct sequencing methods.
We identified 70 LGMD2A mutant patients: 53 (76%) had variable degree of protein deficiency and
17 (24%) had normal calpain-3 amount. We calculated that the probability of having LGMD2A is
very high when patients show a complete calpain-3 deficiency (84.4%) and progressively decreases
with the amount of protein; this new data offers an important tool for genetic counseling when only
protein data are available.
A total of 47 different CAPN-3 gene mutations were detected, 22 of which are new. In our
population, 86% of mutant alleles were concentrated in 7 exons (1,4,5,8,10,11,21).
The prevalence of LGMD2A in North-Eastern Italy is 9.5 per million. In the Venetia district and in
Friuli region it appears particularly frequent due to the recurrence of single mutations (a founder
effect is likely).
This study reports the largest collection of LGMD2A patients so far where both protein and gene
mutation were obtained to draw genotype/protein/phenotype correlations and provide insights into
critical protein domain.